References

Identification and characterization of a spinal muscular atrophy-determining gene

10.1016/0092-8674(95)90460-3 · 1995 · External reference

Newborn Screening and Birth Prevalence for Spinal Muscular Atrophy in the US

10.1001/jamapediatrics.2024.1911 · 2024 · External reference

Spinal Muscular Atrophy: More than a Disease of Motor Neurons?

10.2174/1566524016666161128113338 · 2016 · External reference

Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease

10.1016/j.pediatrneurol.2020.01.003 · 2020 · External reference

Correlation between severity and SMN protein level in spinal muscular atrophy

10.1038/ng0797-265 · 1997 · External reference

The survival motor neuron protein in spinal muscular atrophy

10.1093/hmg/6.8.1205 · 1997 · External reference

Association between centromeric deletions of the SMN gene and sporadic adult-onset lower motor neuron disease

10.1002/ana.410430513 · 1998 · External reference

A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2

10.1093/hmg/8.7.1177 · 1999 · External reference

A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy

10.1073/pnas.96.11.6307 · 1999 · External reference

An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN

10.1093/hmg/9.2.259 · 2000 · External reference

A novel function for the survival motoneuron protein as a translational regulator

10.1093/hmg/dds474 · 2013 · External reference

SMN and symmetric arginine dimethylation of RNA polymerase II C-terminal domain control termination

10.1038/nature16469 · 2016 · External reference

Smn, the spinal muscular atrophy–determining gene product, modulates axon growth and localization of β-actin mRNA in growth cones of motoneurons

10.1083/jcb.200304128 · 2003 · External reference

alpha-COP binding to the survival motor neuron protein SMN is required for neuronal process outgrowth

10.1093/hmg/ddv428 · 2015 · External reference

The spinal muscular atrophy disease protein SMN is linked to the Golgi network

10.1371/journal.pone.0051826 · 2012 · External reference

Ribonucleoprotein Assembly Defects Correlate with Spinal Muscular Atrophy Severity and Preferentially Affect a Subset of Spliceosomal snRNPs

10.1371/journal.pone.0000921 · 2007 · External reference

SMN Deficiency Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in Splicing

10.1016/j.cell.2008.03.031 · 2008 · External reference

SMN, profilin IIa and plastin 3: a link between the deregulation of actin dynamics and SMA pathogenesis

10.1016/j.mcn.2009.05.009 · 2009 · External reference

Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model

10.1093/hmg/ddq021 · 2010 · External reference

Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice

10.1016/j.ajhg.2008.01.014 · 2008 · External reference

Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model

10.1038/nature10485 · 2011 · External reference

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

10.1056/nejmoa1702752 · 2017 · External reference

Patients' Perceptions of Nusinersen Effects According to Their Responder Status

10.3390/jcm13123418 · 2024 · External reference

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

10.1038/s41591-025-04193-6 · 2026 · External reference

Onasemnogene Abeparvovec: First Global Approval

10.1007/s40265-019-01162-5 · 2019 · External reference

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

10.1056/nejmoa1706198 · 2017 · External reference

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

10.1016/s1474-4422(21)00001-6 · 2021 · External reference

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

10.1016/s1474-4422(21)00251-9 · 2021 · External reference

Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study

10.1212/wnl.0000000000210268 · 2025 · External reference

Challenges and opportunities in spinal muscular atrophy therapeutics

10.1016/s1474-4422(23)00419-2 · 2024 · External reference

Combination disease-modifying treatment in spinal muscular atrophy: A proposed classification

10.1002/acn3.51889 · 2023 · External reference

Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy

10.2147/ijgm.s369021 · 2022 · External reference

Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy

10.3390/pharmaceutics15061764 · 2023 · External reference

Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)

10.3233/jnd-221560 · 2023 · External reference

Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial

10.1038/s41591-025-04119-2 · 2026 · External reference

Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial

10.1038/s41591-025-04103-w · 2026 · External reference

Risdiplam: First Approval

10.1007/s40265-020-01410-z · 2020 · External reference

A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier

10.1111/bcp.13786 · 2019 · External reference

Risdiplam in Type 1 Spinal Muscular Atrophy

10.1056/nejmoa2009965 · 2021 · External reference

The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability

10.1016/j.nmd.2009.11.014 · 2010 · External reference

Update on Biomarkers in Spinal Muscular Atrophy

10.1177/11772719211035643 · 2021 · External reference

Biomarker for Spinal Muscular Atrophy: Expression of SMN in Peripheral Blood of SMA Patients and Healthy Controls

10.1371/journal.pone.0139950 · 2015 · External reference

Analysis of the mRNA transcripts of the survival motor neuron (SMN) gene in the tissue of an SMA fetus and the peripheral blood mononuclear cells of normals, carriers and SMA patients

10.1016/s0022-510x(99)00325-1 · 2000 · External reference

Evaluation of Peripheral Blood Mononuclear Cell Processing and Analysis for Survival Motor Neuron Protein

10.1371/journal.pone.0050763 · 2012 · External reference

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study

10.1002/acn3.283 · 2016 · External reference

A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls

10.1371/journal.pone.0167087 · 2016 · External reference

Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol

10.1136/jmedgenet-2018-105482 · 2019 · External reference

Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study

10.1371/journal.pone.0035462 · 2012 · External reference

SMA-MAP: a plasma protein panel for spinal muscular atrophy

10.1371/journal.pone.0060113 · 2013 · External reference

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development

10.3233/jnd-230054 · 2023 · External reference

Neurofilament as a potential biomarker for spinal muscular atrophy

10.1002/acn3.779 · 2019 · External reference

Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment

10.1177/1756286419846058 · 2019 · External reference

Neurofilament light chain and profilin-1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen

10.1111/ene.16393 · 2024 · External reference

Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders

10.1007/s12035-019-01698-3 · 2020 · External reference

Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy

10.1111/jnc.14953 · 2020 · External reference

Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy

10.3390/jcm12206696 · 2023 · External reference

Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy

10.1111/ene.15331 · 2022 · External reference

Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy

10.1007/s00415-024-12670-0 · 2024 · External reference

Multi-omics profiling in spinal muscular atrophy (SMA): investigating lipid and metabolic alterations through longitudinal CSF analysis of Nusinersen-treated patients

10.1007/s00415-025-12909-4 · 2025 · External reference

Identifying novel response markers for spinal muscular atrophy revealed by targeted proteomics following gene therapy

10.1038/s41434-025-00513-0 · 2026 · External reference

Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy

10.1007/s00018-024-05426-6 · 2024 · External reference

Survival Motor Neuron Protein is Released from Cells in Exosomes: A Potential Biomarker for Spinal Muscular Atrophy

10.1038/s41598-017-14313-z · 2017 · External reference

Label-free quantitative proteomic analysis of extracellular vesicles released from fibroblasts derived from patients with spinal muscular atrophy

10.1002/pmic.202000301 · 2021 · External reference

Biological properties of extracellular vesicles and their physiological functions

10.3402/jev.v4.27066 · 2015 · External reference

Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease

10.1007/s13365-018-0695-4 · 2019 · External reference

The emerging role of exosomes in mental disorders

10.1038/s41398-019-0459-9 · 2019 · External reference

Extracellular Vesicles as Therapeutics for Brain Injury and Disease

10.2174/1381612825666191014164950 · 2019 · External reference

Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases

10.1016/j.jconrel.2017.07.001 · 2017 · External reference

DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients

10.18632/oncotarget.13635 · 2017 · External reference

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

10.1038/ncb1800 · 2008 · External reference

Delivery of Therapeutic Agents to the Central Nervous System and the Promise of Extracellular Vesicles

10.3390/pharmaceutics13040492 · 2021 · External reference

Exomap1 mouse: a transgenic model for in vivo studies of exosome biology

10.1016/j.vesic.2023.100030 · 2023 · External reference

Bioengineering extracellular vesicle cargo for optimal therapeutic efficiency

10.1016/j.omtm.2024.101259 · 2024 · External reference

Extracellular vesicles efficiently deliver survival motor neuron protein to cells in culture

10.1038/s41598-025-90083-3 · 2025 · External reference

Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles

10.1007/s00018-011-0689-3 · 2011 · External reference

Extracellular vesicles, new actors in the search for biomarkers of dementias

10.1016/j.neurobiolaging.2018.10.006 · 2019 · External reference

Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases

10.3109/21678421.2014.905606 · 2014 · External reference

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study

10.1016/j.jalz.2014.06.008 · 2015 · External reference

Identification of distinct circulating exosomes in Parkinson's disease

10.1002/acn3.175 · 2015 · External reference

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial

10.1001/jamaneurol.2018.4304 · 2019 · External reference

Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV

10.1097/qad.0000000000001595 · 2017 · External reference

Higher exosomal tau, amyloid-beta 42 and IL-10 are associated with mild TBIs and chronic symptoms in military personnel

10.1080/02699052.2018.1471738 · 2018 · External reference

An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients

10.1016/j.nmd.2007.05.009 · 2007 · External reference

Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III

10.1177/0883073811420294 · 2011 · External reference

Prospective cohort study of spinal muscular atrophy types 2 and 3

10.1212/wnl.0b013e318271f7e4 · 2012 · External reference

What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancer

10.1016/j.bbcan.2018.11.006 · 2019 · External reference

Advances in extracellular vesicle isolation methods: a path towards cell-type specific EV isolation

10.20517/evcna.2023.14 · 2023 · External reference

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines

10.1080/20013078.2018.1535750 · 2018 · External reference

Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

10.1002/jev2.12404 · 2024 · External reference

Opening the window: the care for carrier and perinatal screening for spinal muscular atrophy

10.1016/j.nmd.2016.06.459 · 2016 · External reference

Early treatment is a lifeline for infants with SMA

10.1038/s41591-022-01889-x · 2022 · External reference

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

10.1038/s41591-022-01866-4 · 2022 · External reference

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

10.1038/s41591-022-01867-3 · 2022 · External reference

Systematic Review and Meta-analysis of Long-Term Nusinersen Effectiveness in Adolescents and Adults with Spinal Muscular Atrophy

10.1007/s12325-025-03260-1 · 2025 · External reference

Assessment of safety and efficacy of risdiplam treatment in adults with spinal muscular atrophy

2025 · External reference

Abnormal fatty acid metabolism is a core component of spinal muscular atrophy

10.1002/acn3.50855 · 2019 · External reference

Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients

10.1016/j.ab.2012.06.004 · 2012 · External reference

Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes

10.2337/db17-1308 · 2018 · External reference

Microvesicles as cell-cell messengers in cardiovascular diseases

10.1161/circresaha.113.300858 · 2014 · External reference

Circulating small extracellular vesicles in Alzheimer's disease: a case-control study of neuro-inflammation and synaptic dysfunction

10.1186/s12916-024-03475-z · 2024 · External reference

Methodological Guidelines to Study Extracellular Vesicles

10.1161/circresaha.117.309417 · 2017 · External reference

A beginner's guide to study extracellular vesicles in human blood plasma and serum

10.1002/jev2.12400 · 2024 · External reference

Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying alpha-Synuclein-Containing Extracellular Vesicles

10.1212/wnl.0000000000011853 · 2021 · External reference

Severe Traumatic Brain Injury Induces Early Changes in the Physical Properties and Protein Composition of Intracranial Extracellular Vesicles

10.1089/neu.2017.5515 · 2019 · External reference

Nanoparticles in 472 Human Cerebrospinal Fluid: Changes in Extracellular Vesicle Concentration and miR-21 Expression as a Biomarker for Leptomeningeal Metastasis

2020 · External reference

Cerebrospinal fluid extracellular vesicles undergo age dependent declines and contain known and novel non-coding RNAs

10.1371/journal.pone.0113116 · 2014 · External reference

Age-Related Changes in Plasma Extracellular Vesicle Characteristics and Internalization by Leukocytes

10.1038/s41598-017-01386-z · 2017 · External reference

Characterization of soluble vs membrane-bound human placental 5'-nucleotidase

10.1016/0006-291x(90)91601-n · 1990 · External reference

Multiple steps determine CD73 shedding from RPE: lipid raft localization, ARA1 interaction, and MMP-9 up-regulation

10.1007/s11302-018-9628-1 · 2018 · External reference

ESCRTs - a multi-purpose membrane remodeling device encoded in all life forms

10.1016/j.tim.2025.01.009 · 2025 · External reference

ESCRT-III: a versatile membrane remodeling machinery and its implications in cellular processes and diseases

10.1080/19768354.2024.2380294 · 2024 · External reference

Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I

10.1016/s0092-8674(01)00434-2 · 2001 · External reference

Escrt-III: an endosome-associated heterooligomeric protein complex required for mvb sorting

10.1016/s1534-5807(02)00220-4 · 2002 · External reference

Membrane scission by the ESCRT-III complex

10.1038/nature07836 · 2009 · External reference

The many functions of ESCRTs

10.1038/s41580-019-0177-4 · 2020 · External reference

The midbody interactome reveals unexpected roles for PP1 phosphatases in cytokinesis

10.1038/s41467-019-12507-9 · 2019 · External reference

CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro

10.1093/hmg/ddm309 · 2008 · External reference

ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)

10.1212/01.wnl.0000231510.89311.8b · 2006 · External reference

Hereditary spastic paraparesis: a review of new developments

10.1136/jnnp.69.2.150 · 2000 · External reference

alpha-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease

10.1093/hmg/ddv633 · 2016 · External reference

Loss of skywalker reveals synaptic endosomes as sorting stations for synaptic vesicle proteins

10.1016/j.cell.2011.02.039 · 2011 · External reference

Motor and Sensory Deficits in the teetering Mice Result from Mutation of the ESCRT Component HGS

10.1371/journal.pgen.1005290 · 2015 · External reference

The role of ESCRT during development and functioning of the nervous system

10.1016/j.semcdb.2017.08.013 · 2018 · External reference

Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice

10.1523/jneurosci.4434-08.2009 · 2009 · External reference

At the “junction” of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression

10.2174/15665240113139990044 · 2013 · External reference

Mass Spectrometry-Based Plasma Proteomics: Considerations from Sample Collection to Achieving Translational Data

10.1021/acs.jproteome.9b00503 · 2019 · External reference

Aptamer-based multiplexed proteomic technology for biomarker discovery

10.1371/journal.pone.0015004 · 2010 · External reference

Variability of 7K and 11K SomaScan Plasma Proteomics Assays

10.1021/acs.jproteome.4c00667 · 2024 · External reference

Assessment of variability in the plasma 7k SomaScan proteomics assay

10.1038/s41598-022-22116-0 · 2022 · External reference